Is it time to reduce the doxorubicin dosage in in Hodgkin lymphoma therapy?

Key Points

• This research aims to evaluate whether reducing doxorubicin dosage could be beneficial in Hodgkin lymphoma treatment.
• Review of existing literature on doxorubicin and Hodgkin lymphoma
• Analysis of dosage effects on treatment outcomes
• Consideration of patient safety and long-term effects
• Reduced dosages may maintain treatment efficacy while lowering toxicity risks
• Insights suggest possible improvement in patient quality of life
• Further studies are needed to confirm safety and effectiveness